Jacob Lanyak

Jacob Lanyak asked about the anticipated impact of the CREST-2 trial on LeMaitre Vascular's carotid revascularization and carotid artery stenting business, and how this was factored into guidance. He also requested a breakdown of price versus volume contributions within various product categories for the last quarter.

Answer

President Dave Roberts noted a record quarter for carotid shunts, with 15% of worldwide sales from carotid procedures and 80% of shunt units sold OUS. He discussed CREST-2 findings, highlighting exclusion criteria for stenting and the close statistical outcome, concluding the business is well-positioned due to geographic diversification. CEO George LeMaitre declined to provide a breakdown of price versus volume by category for simplicity.